Sionna Therapeutics, Inc. (SION)

NGM – Real vaqt narxi. Valyuta: USD

42.18

-0.59 (-1.38%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

42.18

-0.00 (-0.00%)

Bozordan keyin: Jun 26, 2026, 4:36 PM EDT

10.06.2026

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

27.05.2026

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

WALTHAM, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in the following upcoming investor events:

13.05.2026

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th, 2026, at 2:05 p.m. ET.

12.05.2026

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026 Maintained strong cash position with approximately $289.9 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

27.04.2026

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026

07.04.2026

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14th, 2026.

31.03.2026

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Jennifer Fitzpatrick sold 10,250 shares for a total of approximately $347,000 on March 5, 2026. This transaction represented 100.00% of her direct common stock holdings, reducing direct ownership of common stock to zero.

Videolar

No Data

There is no data to display

Press-relizlar

12.05.2026

Sionna Therapeutics Reports First Quarter 2026 Financial Results

27.04.2026

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Topline data is on track for anticipated readout in the summer of 2026 Topline data is on track for anticipated readout in the summer of 2026

07.04.2026

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

02.03.2026

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is on track with topline data anticipated in mid-2026 Maintained strong cash position with approximately $310.3 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

Sionna Therapeutics, Inc. (SION)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Videolar

No Data

Press-relizlar

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Videolar

No Data

Press-relizlar

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Search stocks

Sionna Therapeutics, Inc. (SION)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Videolar

No Data

Press-relizlar

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Sionna Therapeutics, Inc. (SION) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences

Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story

Videolar

No Data

Press-relizlar

Sionna Therapeutics Reports First Quarter 2026 Financial Results

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results